vimarsana.com

Latest Breaking News On - Behavior medicine inc - Page 1 : vimarsana.com

FDA Clears Cingulate to File NDA for CTx-1301 in the Treatment of ADHD

The company has announced plans to submit the NDA in the first half of 2025.

United-states
American
Ann-childress
Shanej-schaffer
American-professional-society
Drug-administration
Behavior-medicine-inc
Cingulate-inc
New-drug-application
Related-disorders
Annual-meeting
Permanent-product-measure

FDA Clears Cingulate to File for Marketing Approval of

Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application Advancing Discussions with Commercialization Partners.

United-states
Kansas
Kansas-city
American
Shanej-schaffer
Matt-kreps
Thomas-dalton
Ann-childress
Darrow-associates
Exchange-commission
Nasdaq
Psych-congress-first-annual-poster

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application CTx-1301 Could Benefit >60% of ADHD Patients Currently .

United-states
Kansas-city
Kansas
American
Shanej-schaffer
Matt-kreps
Thomas-dalton
Ann-childress
Drug-administration
Behavior-medicine-inc
Platform-technology
Securities-exchange

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Cingulate to Host CNS Key Opinion Leader Panel in New York City
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
Manhattan
New-york
Kansas-city
Kansas
Matthew-brams
Thomas-daltonvice
Ann-childress
Shanej-schaffer
Greg-mattingly
Raul-silva
Cingulate-inc

Cingulate to Host CNS Key Opinion Leader Panel in New York

Expert Analysis of Cingulate, its Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delivery Platform Innovations.

New-york
United-states
Kansas-city
Kansas
Manhattan
Melyssa-weible
Matthew-brams
Matt-kreps
Raul-silva
Greg-mattingly
Shanej-schaffer
Ann-childress

vimarsana © 2020. All Rights Reserved.